Osmol Therapeutics

Founded in 2016 and headquartered in New Haven, Connecticut, Osmol Therapeutics is dedicated to developing treatments to prevent chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI). The company's core mission is to enhance care and transform lives by creating compassionate and effective treatment paths for patients at risk of these debilitating conditions. Osmol Therapeutics focuses on addressing critical challenges in cancer treatment, aiming to improve the quality of life for cancer patients worldwide.

Osmol Therapeutics has garnered attention for its innovative approach and has attracted notable investors and affiliations within the biotech and medical communities. The company's key achievements include advancing its lead therapeutic candidates through preclinical and early clinical development stages. By targeting the unmet needs in cancer supportive care, Osmol Therapeutics has made a significant impact on the field, offering hope to patients suffering from the side effects of life-saving chemotherapy treatments.